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Abstract. The cell surface receptor Fas (FasR, Apo-1, 
CD95) and its ligand (FasL) are mediators of apoptosis 
that have been shown to be implicated in the peripheral 
deletion of autoimmune cells, activation-induced T cell 
death, and one of the two major cytolytic pathways me- 
diated by CD8 + cytolytic T cells. To gain further under- 
standing of the Fas system, we have analyzed Fas and 
FasL expression during mouse development and in 
adult tissues. In developing mouse embryos, from 16.5 
d onwards, Fas mRNA is detectable in distinct cell 
types of the developing sinus, thymus, lung, and liver, 
whereas FasL expression is restricted to submaxillary 
gland epithelial cells and the developing nervous sys- 
tem. Significant Fas and FasL expression were ob- 
served in several nonlymphoid cell types during em- 
bryogenesis, and generally Fas and FasL expression 
were not localized to characteristic sites of programmed 
cell death. In the adult mouse, RNase protection analy- 
sis revealed very wide expression of both Fas and FasL. 
Several tissues, including the thymus, lung, spleen, 
small intestine, large intestine, seminal vesicle, pros- 
tate, and uterus, clearly coexpress the two genes. Most 
tissues constitutively coexpressing Fas and FasL in the 
adult mouse are characterized by apoptotic cell turn- 
over, and many of those expressing FasL are known to 
be immune privileged. It may be, therefore, that the Fas 
system is implicated in both the regulation of physio- 
logical cell turnover and the protection of particular tis- 
sues against potential lymphocyte-mediated damage. 
OPTOSIS is  an  active cell  death  process that  takes 
place  in  a  spectrum  of physiological  conditions 
such as embryonic development and  normal cell 
turnover, but is also the mode of cell death resulting from 
CD8 ÷ T  cell-mediated  cytotoxicity (Steller,  1995). The 
mechanisms that regulate apoptotic cell death are there- 
fore crucial for normal development and homeostasis. 
The Fas receptor (FasR, Apo-1 CD95)  1  is a cysteine-rich 
type I membrane protein belonging to the tumor necrosis 
factor  (TNF)  NGF  receptor  family,  and  shows  high  se- 
quence similarities to CD27, CD30, CD40, and the lympho- 
toxin-13 receptor (Nagata and Golstein, 1995; Smith et al., 
1994). Upon contact with cross-linking  antibodies  or  the 
natural ligand (FasL), cells expressing Fas undergo apop- 
tosis rapidly (Itoh et al., 1991; Trauth et al., 1989) by way 
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of a rapid intracellular signaling  pathway dependent on a 
distinct  cytoplasmic  motif  called  the  "death  domain" 
(Hofmann  and  Tschopp,  1995; Itoh  and  Nagata,  1993; 
Tartaglia et al., 1993). FasL is a type II membrane protein 
and  a  member  of the  protein  superfamily  consisting  of 
TNF-a, lymphotoxin-et  (TNF-[3), lymphotoxin-13, CD27L, 
CD30L, CD40L, and 4-1BBL (Smith et al., 1994). 
Considerable knowledge of the Fas system's biological 
relevance has been provided by mutant  mice.  Mice ho- 
mozygous for lpr (lymphoproliferation)  or gld  (general- 
ized disease) develop a progressive autoimmune disorder 
that  resembles  systemic  lupus  in  humans  (Cohen  and 
Eisenberg, 1991). These mice also suffer from a large accu- 
mulation  of  nonmalignant  CD4-CD8-  T  cells  in  the 
spleen and lymph nodes. Genetic cloning and the analysis 
of gene structure has indicated that lpr is a recessive muta- 
tion in Fas (Watanabe et al., 1992a), whereas the gld phe- 
notype is a mutation in the gene for FasL (Lynch et al., 
1994; Takahashi et al., 1994). 
The Fas system has been shown to play a crucial  role in 
the peripheral deletion of autoimmune cells (Kotzin et al., 
1988; Rozzo et al., 1994; Singer and Abbas, 1994) and in 
activation-induced  T  cell  death  (Alderson  et  al.,  1995; 
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portant effector molecule of cytolytic T lymphocytes, one 
of the two major cytolytic  pathways of CD8  ÷ cytolytic  T cells 
being dependent on Fas (Kagi et al., 1994; Lowin et al., 1994). 
Although detailed studies have described the function 
of Fas and its ligand in the immune system, relatively little 
is  known about its role outside of the lymphoid system. 
Recent studies have shown that both Fas and FasL are ex- 
pressed  in  certain  nonlymphoid tissues  (Bellgrau et al., 
1995; Griffith et al.,  1995; Leithauser et al., 1993; Suda et 
al., 1993; Watanabe et al., 1992b), but little is known about 
their function(s) at these sites. To gain further understand- 
ing of the Fas system and an eventual role in mammalian 
development, we  have  analyzed Fas  and  FasL gene ex- 
pression during mouse development and in adult tissues. 
Materials and Methods 
Materials. Adult  NMRI  female  mice  (Kleintierfarm,  Mad6rin,  Basel) 
were housed with males for one night and monitored for the appearance 
of a vaginal plug the next morning. Noontime on the day of the vaginal 
plug was considered as day 0.5 of gestation. Segments of uteri or, at later 
stages, whole embryos were dissected, embedded in Tissue-Tek (Miles, 
Ames Division,  Elkhart,  IN),  frozen  in  precooled  methylbutane,  and 
stored at  -70°C. For each time point, three to four embryos were ana- 
lyzed, and 20-40 sections were prepared per embryo. 
The polyclonal (PE62) and monoclonal (Hll) antibodies used were di- 
rected  against a  peptide spanning amino acids 197-218 of mouse FasL 
(Hahne et al., 1995).  The polyclonal rabbit antibody was affinity purified 
on its antigen. The monoclonal antineurofilament 200 antibody (Sigma 
Immunochemicals, St. Louis, MO) was a kind gift from Y. Sagot (Univer- 
sity of Geneva, Geneva, Switzerland), and the monoclonal antivimentin 
antibody (MCTA3) was a kind gift from E. Reiehmann (ISREC, Epalin- 
ges, Switzerland). Secondary antibodies were FITC-conjugated, affinity- 
purified F(ab)z fragment anti-rabbit or anti-rat IgG antibodies (Dianova, 
Hamburg, Germany or Sigma), biotinylated rabbit anti-mouse IgG anti- 
bodies (Dako, Glostrup, Denmark), and FITC sheep anti-mouse IgG/an- 
tibodies (Serotec, Oxford, UK). 
Plasmid Constructions, In Vitro Transcription, RNA Isolation and RNase 
Protection Analysis. The plasmid containing the 1.5-kb mouse Fas cDNA 
was a kind gift from P. Erb (University of Basel, Basel, Switzerland), and 
was used as such for in vitro transcription of sense and antisense probes 
that were used for in situ hybridization. For RNase protection analysis, a 
HindIII/DralI  fragment containing the 5' 974-bp of this cDNA was sub- 
cloned into pBluescript KS (Stratagene, La Jolla,  CA),  and was subse- 
quently linearized at the XhoI site to yield a protected fragment of ~203 
nucleotides (nt). Mouse FasL cDNA was generated by PCR using primers 
5'-ATG CAG CAG CCC GTG AAT TAC-3' and 5'-CCA TAT CTG GCC 
AGT AGT GC-3' designed to amplify cDNA corresponding to amino acid 
residues 1-237 of FasL, which was subsequently subcloned into a  pBK- 
CMV vector (Stratagene). For RNase protection analysis, a PstI fragment 
containing the 3' end of the FasL cDNA was deleted, leaving a 5' 320-bp 
fragment of the cDNA in the pBK-CMV vector. This template was linear- 
ized at the EcoRI site to yield a protected fragment of ~320 nt. The pT7 
RNA 18S plasmid (Ambion, Austin, TX), containing a highly conserved 
region of the human 18S ribosomal RNA gene, was linearized at the Hind- 
III site to create a template that yields an 80-nt protected fragment that 
sometimes migrates as a doublet. Sense and antisense radiolabeled cRNAs 
were synthesized from the above templates by in vitro transcription with 
32p-labeled  uridine  5'=triphosphate  (UTP)  (400  Ci/mmol),  35S-labeled 
UTP (400 Ci/mmol), or 3H-labeled UTP and CTP (40 and 20 Ci/mmol, re- 
spectively). For in situ hybridization, ass- and 3H-labeled probes were sub- 
sequently reduced to an average size of 50-100 nt by mild alkaline hydrolysis 
as previously described (French et al., 1993). For the synthesis  of 35S-labeled 
probes, all reactions were performed in 10 mM DTT. 
Total RNA was isolated from 20 selected adult tissues that were col- 
lected from 3-too-old NMRI mice as described (French et al., 1993).  For 
RNase protection assays, 15 I~g of total RNA was hybridized for 16 h  to 
32p-labeled  Fas or FasL cRNAs (300,000 cpm/sample, specific activity 1.2 × 
I0  s cpm/ixg) along with a final twofold excess of cold plus 32p-labeled 18S 
cRNAs (1,000 cpm/sample, specific activity 0.5 ×  106 cpm/ixg) at 42°C as 
described (Belin et al., 1989).  A  twofold excess of 18S cRNAs was previ- 
ously shown to be sufficient to detect small variations in RNA loading. 
Unhybridized RNA was digested with RNase A, followed by proteinase K 
digestion, phenol/chloroform  extraction,  and  sodium acetate  precipita- 
tion. Hybridized RNA was then denatured at 90°C,  separated in a  5% 
polyacrylamide gel, and exposed to x-ray films. 
In Situ Hybridization  and lmmunafluorescence. Cryostat sections (6--8 rzm) 
were air dried, fixed in 4% (wt/vol) paraformaldehyde in PBS, used imme- 
diately for immunofluorescence, or stored in 70% ethanol at 4°C before in 
situ hybridization.  In  situ hybridization  and  immunofluorescence were 
performed as described (French et al., 1992; 1993). After in situ hybridiza- 
tion, slides were either directly exposed to x-ray films (sections hybridized 
to 35S-labeled  cRNAs) and developed after 14 d of exposure, or immersed 
in NTB-2 emulsion (sections hybridized to 3H-labeled cRNAs), developed 
after  a  12-16-wk  exposure, and counterstained in  1%  methylene blue. 
Controls of specificity for in situ hybridizations included the systematic 
use of sense cRNA probes in each experiment. For immunofluorescence 
analysis, controls of specificity included incubation of sections with non- 
immune rabbit or rat Igs, incubation in the absence of the first antibody, 
and in the case of FasL, preincubation of the primary antibody for 30 min 
with a 10-fold (wt/wt) excess of FasL (AA 197-218)  or unspecific peptide. 
Results 
Mouse Embryos Contain Fas and FasL mRNA 
from 16.5 d Onwards 
The regional distribution of Fas and FasL mRNA in mouse 
embryos was determined by in situ hybridization of the re- 
spective 35S-labeled  cRNA probes to sagittal sections of 
whole embryos ranging from 5.5 to 18.5 d of development, 
and subsequent exposure to x-ray films. Using this tech- 
nique, Fas and FasL mRNA were detected in certain mac- 
roscopically identifiable organs  from  16.5  d  of develop- 
ment onwards  (Fig.  1).  No signal  was  detected with the 
sense Fas and FasL cRNA probes (Fig. 1 and not shown). 
As shown in Fig. 1, at 16.5 d of development, Fas mRNA is 
detectable in the developing sinus, thymus, lung, and liver. 
At the same stage of development, a different pattern of 
expression was  observed for FasL, which is macroscopi- 
cally detectable in the developing brain, spinal cord, and 
submaxillary gland. The regional distribution of Fas and 
FasL mRNA was very similar in 18.5-d-old embryos (not 
shown). 
Fas mRNA Is Abundant in Developing Thymocytes 
and Upper Respiratory  Tract Epithelial  Cells 
The cellular distribution of Fas mRNA in embryos ranging 
from 5.5 to 18.5 d  of development was determined by in 
situ  hybridization  using  3H-labeled  cRNA  probes.  The 
strongest levels of embryonic Fas gene expression were 
detected in the thymus and upper respiratory tract. In the 
thymus,  both  the  cortical  and  medullary  regions  were 
strongly labeled from 16.5 d of development onwards (Fig. 
2, A and B), and the labeling observed is specific in that no 
signal was detectable in sections hybridized to the sense 
probe (Fig. 2, C and D). The distribution and morphology 
of the  cells  containing  Fas  transcripts  suggest  that  thy- 
mocytes account for the majority of Fas gene expression at 
this stage of development. Considerable amounts of Fas 
mRNA were also detectable at 16.5 and 18.5 d of develop- 
ment in the respiratory epithelial cells of the developing 
nasal cavities and sinuses (Fig. 2, E-H). A  clear cutoff was 
seen at the limit between the respiratory and the olfactory 
epithelium, with  no Fas  mRNA  detectable in  the  latter 
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tion of Fas and FasL mRNA 
in 16.5-d-old mouse embryos 
as assessed by in situ hybrid- 
ization  of 35S-labeled cRNA 
probes to sagittal cryostat tis- 
sue  sections.  Fas  mRNA 
(Fas) is detectable in the de- 
veloping  sinus (Si),  thymus 
(Th),  lung  (Lu),  and  liver 
(Li). The inset shows the thy- 
mus,  lung, and liver  several 
sections further in an embryo 
of  the  same  age.  FasL 
mRNA (FasL) is detectable 
in the developing brain (Br), 
spinal  cord  (SC),  and  sub- 
maxillary gland (Gl). No sig- 
nal is detected in an adjacent 
section hybridized to the Fas 
sense probe (Sense). The section on the far right was counterstained with hematoxylin and eosin (H.E.), and it shows the localization of 
macroscopically identifiable organs. Vertebrae (Ve), kidney (Ki), gut (Gu), duodenum (Du), and heart (He). Photographs were taken 
after 15 d (Fas, FasL, and Sense) of exposure at room temperature. 
(Fig. 2, E  and F). Less intense, yet still significant Fas ex- 
pression was seen in the liver from 16.5 d onwards (Fig. 2, 
I and J). The developing liver is a predominant site of fetal 
hematopoiesis during embryogenesis, and in situ hybrid- 
ization clearly shows that Fas mRNA is restricted to cells 
morphologically identified as hepatocytes (Fig. 2, Iand J, 
arrows), whereas no message is detectable in the charac- 
teristically more darkly counterstained groups of fetal he- 
matopoietic  cells.  Lower  but  significant  levels  of  Fas 
mRNA were also detectable in epithelial ceils of the de- 
veloping lung and gut from 16.5 d of development onwards 
(Table I). In the lung, at 16.5 d of development, Fas mRNA 
was localized to epithelial cells of developing bronchioles, 
whereas in 18.5-d-old embryos, message was also detect- 
able in developing alveoli (Table I). Taken together, Fas 
gene expression does not appear to be exclusively restricted 
to cells of the lymphoid cell lineage during embryogenesis, 
but is also detectable in hepatocytes and certain epithelial 
cell types. 
Embryonic FasL Gene Expression Is Detected in Neurons 
and Submaxillary Gland Epithelial Cells. In situ hybridization 
of the FasL cRNA to cryostat sections of developing mouse 
embryos also revealed specific labeling in distinct cell types 
from 16.5 d of development onwards (Table I). For exam- 
ple, high levels of FasL mRNA were detectable within cer- 
tain acinar glandular cells of the developing submaxillary 
gland (Fig. 3, A  and B). In contrast, no signal was detect- 
able in the epithelium lining the ducts of the submaxillary 
gland  (Fig. 3, A  and B) or in sections hybridized to the 
sense probe (Fig. 3, C and D). Analysis by immunofluores- 
cence using an affinity-purified antibody directed against a 
peptide of mouse FasL (Hahne et al.,  1995) revealed an 
identical pattern of staining within the salivary gland, with 
strong labeling present on certain glandular epithelial cells 
(Fig. 3, E  and F). Specificity of this immunolabeling for 
FasL was confirmed by the identical staining observed us- 
ing a mAb directed against the same domain of FasL, the 
abrogation  of staining  by  coincubation  of the  antibody 
with an excess of FasL peptide (Fig. 3 G), and the absence 
of staining with control Igs or in the absence of the first an- 
tibody. The developing nervous system (brain and spinal 
cord) was shown to contain significant levels of FasL mRNA 
from 16.5  d  onwards by in situ hybridization (Fig.  1 and 
Table I). Analysis by immunofluorescence with anti-FasL 
antibodies revealed clear and specific labeling of neurons 
and axons throughout the nervous system. Strong FasL ex- 
pression  in  neurons  and  axons  of the  developing spinal 
ganglia is illustrated in Fig. 3, H  and L  Similar FasL ex- 
pression was detectable by immunofluorescence in axons 
below the sensory epithelium of the developing inner ear 
(Fig. 3 J). Identification of this structure was confirmed by 
an identical staining pattern observed on adjacent sections 
with an antineurofilament antibody (Fig. 3 K). Taken to- 
gether, from 16.5 d of embryogenesis onwards, FasL gene 
expression is  not  restricted to  the  developing lymphoid 
system,  and  it  predominates  in  nonlymphoid cell  types 
within  the  developing nervous  system  and  submaxillary 
gland. 
Coexpression  of Fas and FasL  Genes  in  Several Adult 
Mouse Tissues. Fas and FasL mRNA content was assessed 
in 20 adult mouse tissues by RNase protection analysis. As 
shown in Fig. 4, both Fas and FasL are widely expressed in 
adult  mouse  tissues,  and  Fas  appears  on  average  more 
abundant as revealed by the long exposure time needed to 
detected FasL mRNA. 
Fas mRNA was detected in all tissues tested (Fig. 4 A). 
High amounts of Fas mRNA were detectable in the skin, 
heart, lung, thymus, small intestine, and liver, and moder- 
ate amounts were detectable in the muscle, bone, spleen, 
stomach,  large  intestine,  adrenal  gland,  seminal  vesicle, 
prostate, and uterus. A  protected mRNA fragment is also 
clearly detectable, although in lower amounts, in the brain, 
kidney, pancreas, testis, and ovary. 
Using the same assay, we also observed wide expression 
of the FasL gene, although at lower levels (Fig. 4 B). High- 
est levels of FasL message were detectable in the spleen, 
small intestine, testis, and uterus; comparatively moderate 
levels in the lung, thymus, large intestine, and seminal ves- 
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18.5-d-old Mouse Embryos 
16.5 d  18.5 d 
Fas  FasL  Fas  FasL 
Epithelia 
Keratinocytes  -  - 
Choroid  plexus  -  - 
Respiratory  epithelium  +  +  +  - 
Otic  epithelium  -  - 
Retinal  pigment  epithelium  -  - 
Proliferative  lens epithelium  -  - 
Salivary  glands  -  +  +  + 
Bronchial  epithelium  +  - 
Stomach  -  - 
Intestine  +  - 
Kidney  tubular  epithelium  -  - 
Testes  NS  NS 
Biliary  epithelium  -  - 
Pancreatic  acini and  ductules  -  - 
Hepatocytes  +  - 
Ventricular  neuroepithelium  -  - 
Thymus  +  +  + 
Spleen  -  - 
Adrenal  gland  -  - 
Hematopoietic  tissue  -  - 
Neuronal  tissue 
Brain  -  +  + 
Spinal  cord  -  +  + 
Photoreceptor  layers  of the eye  -  - 
Bone  (osteoclasts  or osteoblasts)  -  - 
Endothelia  -  - 
Mesenchyme 
Kidney  -  - 
Lung  -  - 
Skeletal  muscle  -  - 
Heart  muscle  (ventricle)  -  - 
cluding the thymus, lung, spleen, small intestine, large in- 
testine,  seminal  vesicle,  prostate,  and  uterus,  coexpress 
Fas and FasL. 
Sertoli Cells Account for the Strong FasL Gene Expres- 
sion Observed in the Adult Testis. To determine whether the 
FasL gene expression observed by RNase protection anal- 
-  -  ysis in adult tissues may result from cell types other than 
-  -  passenger leukocytes, we have analyzed FasL expression 
+++  +  in the adult testis,  where lymphocytes are rare and FasL 
_  _  mRNA is abundant. Analysis by immunofluorescence re- 
_  _  vealed a distinct pattern of labeling in the cells lining semi- 
-  + + +  niferous tubules that is reminiscent of Sertoli cells (Fig. 5 
++  -  A). Histological features of these cells, as observed on ad- 
-  -  jacent sections stained  with hematoxylin and eosin,  (not 
+  -  shown) and labeling of adjacent sections with antibodies 
NS  NS  to vimentin (Fig. 5 C), an intermediate filament that is spe- 
_  _  cific for Sertoli cells  within seminiferous tubules (Statho- 
_  _  poulos et al., 1989), strongly suggest that FasL is expressed 
+ +  -  by Sertoli cells in the testis. Recent evidence that supports 
-  -  this result has been provided by reverse transcription PCR 
+ +  +  analysis  of FasL gene  expression  in  primary Sertoli  cell 
-  -  cultures (Bellgrau et al.,  1995). Therefore, although FasL 
-  -  is known to be strongly expressed by lymphoid cells in the 
adult  mouse,  the  above  experiments  clearly demonstrate 
that certain nonlymphoid cells also express FasL strongly.  ++ 
++ 
Gene expression was asssessed in a  variety of tissues semiquantitatively by in situ hy- 
bridization of 3H-labeled murine Fas or FasL cRNA probes to frozen cryostat sections 
of  16.5- and  18.5-d-old embryos.  -,  no  mRNA  detectable;  +,  weak labeling;  ++, 
moderate  labeling;  +  +  +,  strong  labeling; NS, not  studied.  No Fas  or FasL mRNA 
was detected in 5.5-, 6.5-, 7.5-, 9.5-, 10.5-, 12.5-, and  14.5-d-old embryos (not shown). 
icle; and low levels in the skin, muscle, bone, brain, kidney, 
stomach, adrenal gland, prostate, and ovary. In the heart, 
liver, and pancreas, no protected FasL mRNA fragment 
was detectable after 16 d of exposure. 
In the  above assays, no protected fragments were  ob- 
served with either the Fas or FasL probes in tRNA con- 
trois, and equal loading of total RNAs was confirmed by 
simultaneously hybridizing all  samples  to  an  18S  rRNA 
probe as an internal control. In the FasL RNAse protec- 
tion assay, a band corresponding to residual full-length un- 
digested FasL probe can be seen in certain samples. 
Despite the overall difference in the levels of Fas  and 
FasL gene expression in  adult tissues,  RNase protection 
analysis  reproducibly demonstrated  that  both  genes  are 
widely expressed and that several adult mouse tissues, in- 
Discussion 
In this study, we analyzed the expression of Fas and FasL 
in  mouse  embryos and  in  the  adult  mouse.  Our  results 
show that Fas  and FasL expression are restricted to dis- 
tinct lymphoid and  nonlymphoid tissues  during late  em- 
bryogenesis of the mouse embryo, and clearly are not only 
expressed  by  developing  lymphoid  cells.  In  the  adult 
mouse, Fas and FasL are widely expressed, and interest- 
ingly, several  tissues  including the  thymus, lung,  spleen, 
small  intestine,  large  intestine,  seminal  vesicle,  prostate, 
and uterus appear to coexpress the two genes. In the adult, 
similarly to the embryo, FasL gene expression does not ap- 
pear to be strictly restricted to lymphoid cell types, since 
significant gene expression is observed in several nonlym- 
phoid tissues.  The demonstration of strong FasL expres- 
sion by Sertoli cells in the testis suggests furthermore that 
passenger  lymphocytes cannot account for the  FasL ex- 
pression that is detected in all adult nonlymphoid tissues. 
Apoptosis is one of the cellular processes that are essen- 
tial for the proper development and shaping of tissues dur- 
ing development. For example, during embryogenesis, ap- 
optotic cell death takes place in the regressing interdigital 
tissue of developing limb buds, in epithelial cells lining the 
palatal shelves before their fusion, in the duodenal mucosa 
during formation of the  villi,  and  while  connections are 
made in the nervous system (Wyllie et al., 1980). Analysis 
of Fas and FasL expression in mouse embryos from 5.5 d 
of  development  onwards  did  not  reveal  expression  at 
Figure 2.  Microscopical localization of Fas mRNA in embryonic mouse tissues by in situ hybridization using 3H-labeled murine Fas 
cRNAs. Fas mRNA is detected in the thymus (A and B), respiratory epithelium lining nasal cavities (E-H), and hepatocytes (arrows) of 
the liver (I and J) of 16.5-d-old embryos. Note the sharp transition (arrowheads) in expression between the respiratory (r) and olfactive 
(o) epithelia (E and F). C and D show the thymus of a 16.5-d-old embryo hybridized to the sense Fas cRNA probe. A, C, E, G, and I are 
dark-field micrographs; B, D, F, H, and J are the corresponding light-field micrographs. Bars, 33 ixm. 
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analysis of Fas (A) and FasL 
(B)  mRNA  in  adult  mouse 
tissues.  15  ~g of total RNA 
prepared from the indicated 
tissues  were  hybridized  to 
the  Fas or  FasL riboprobes 
along  with  an  18S  rRNA 
probe as an internal control. 
Protected  fragments  corre- 
sponding  to  Fas, FasL,  and 
18S are indicated by arrows. 
In A  and B, riboprobes were 
also hybridized to tRNA as a 
negative control. A band cor- 
responding  to  residual  full- 
length  undigested  FasL 
probe can be seen in certain 
lanes (small intestine to sem- 
inal vesicle and ovary in B). 
Exposure time at -80°C was 
4 d for A and 16 d for B. 
known sites of apoptotic cell death during embyogenesis, 
except in the developing nervous system. At 16.5 and 18.5 
d  of development, FasL expression was detectable in neu- 
rons  and  axons  of the  brain,  the  spinal cord,  and  spinal 
ganglia.  In vertebrates,  during  the  period when  neurons 
establish synaptic connections, 20--80%  of all neurons  in 
the  central  and  peripheral nervous  systems  die  (Oppen- 
heim,  1991).  In  the  chick,  the  majority of neuronal  cell 
death takes place between the 13th and 17th day of devel- 
opment  (Oppenheim,  1991).  Although the time of devel- 
opmental neuronal death in the mouse has not been well 
characterized, the site and period of FasL expression coin- 
cides approximately with the extrapolated period of ongo- 
ing cell death in the mouse nervous system. Coexpression 
and colocalization of Fas was not detected in the develop- 
ing nervous system. Although we cannot exclude the pres- 
ence of low amounts of Fas undetectable by in situ hybrid- 
ization, the relevance of FasL expression in the developing 
nervous  system in  the  absence  of detectable Fas and  its 
possible implication in developmental neuronal cell death 
remains to be determined. Since no abnormalities in em- 
bryonic development of lpr  and  gld mice have  been  de- 
scribed to date, it may be that FasL expression is not impli- 
cated in neuronal death, but rather in the protection of the 
Figure 3.  Microscopical localization of FasL mRNA and protein in embryonic mouse tissues by in situ hybridization using 3H-labeled 
murine FasL cRNAs and immunofluorescence using a polyclonal anti-FasL antibody. FasL mRNA (A and B) and protein (E and F) are 
detected in the acinar glandular cells of the submaxillary gland of 16.5-d-old embryos. C and D are sections adjacent to A and B hybrid- 
ized to sense FasL cRNAs. G is a section adjacent to F in which the anti-FasL Ab was preincubated with an excess of FasL peptide. FasL 
is also clearly detectable in neuronal bodies and axons of spinal ganglia in 16.5-d-old embryos (H and/). In the developing inner ear of 
16.5-d-old embryos, FasL is localized to a distinct neuronal structure beneath the sensory epithelium (J), which is also labeled by an an- 
tineurofilament antibody (K). A is a dark-field micrograph, and B is the corresponding light-field micrograph. Bars, 33 ixm. 
French et al. Fas and FasL Expression in Embryos and Adult Mice  341 Figure 5.  Microscopical localization of FasL in the adult mouse testis by immunofluorescence using polyclonal anti-FasL antibody. FasL 
(A) is detected in distinct cells located at the base of seminiferous tubules. Staining of adjacent sections with FasL (B) and vimentin (C) 
antibodies suggests that vimentin-positive Sertoli cells express FasL (arrows). Bars, 33 Ixm. 
nervous system. Indeed, besides the blood-brain barrier, 
FasL  expression on  cells  of the  central nervous  system 
may comprise a  second protection mechanism necessary 
for preventing lymphocyte-mediated damage  within  the 
central nervous system. The brain is known to be an im- 
mune-privileged site,  and  similarly to the  adult  eye and 
testis (Bellgrau et al.,  1995; Griffith et al.,  1995), FasL ex- 
pression in the embryonic and adult brain may protect the 
brain from potentially dangerous immune reactions. 
In contrast to the restricted expression of Fas and FasL 
in embryos, expression of these genes is much more wide- 
spread in adult mice. Previous Northern blot analyses of a 
limited number of adult mouse tissues has shown Fas gene 
expression in  the  lung,  heart,  liver, thymus, kidney and 
ovary (Watanabe et al.,  1992b), whereas FasL has to date 
been detected in the testis, small intestine, kidney, lung, 
spleen, thymus, and eye (Griffith et al.,  1995; Suda et al., 
1993). The analyses performed in this study on a larger ar- 
ray of mouse tissues using a more sensitive technique re- 
vealed wider Fas and FasL gene expression than has been 
so far shown in previous studies. Although Fas and FasL 
mRNA levels clearly differ within the same tissues, our re- 
suits show that several tissues, including the thymus, lung, 
spleen,  small  intestine,  large  intestine,  seminal  vesicle, 
prostate, and uterus, clearly coexpress the two genes. Fas 
and FasL gene expression in these tissues may result from 
passenger leukocytes (Suda et al., 1995). Previous reports, 
however, have shown that Fas is expressed by cells other 
than leukocytes (Leithauser et al., 1993), and the present 
report demonstrates  that  this  is  also  the  case for FasL, 
which is strongly expressed by developing neurons, sub- 
maxillary gland epithelial cells, and Sertoli cells within the 
adult testis. Taken together, it clearly appears that expres- 
sion of Fas and FasL is not solely restricted to lymphoid 
cells. It may be, therefore, that the Fas system is also asso- 
ciated  with  apoptosis  of certain nonlymphoid cell types 
other than those known to date (Ogasawara et al., 1993). 
Interestingly, several of the tissues that coexpress Fas and 
FasL are also characterized by high rates of cell turnover. 
Furthermore, in the thymus, spleen, small intestine, pros- 
tate, and uterus, apoptotic cell death has been identified, 
and moreover, evidence suggests that in several of these 
tissues apoptosis is implicated in the control of cell turn- 
over and tissue homeostasis (Benedetti et al., 1988; Gavri- 
eli et al., 1992; Kerr and Searle, 1973; Liu et al., 1989; Ro- 
tello et al., 1992; Surh and Sprent, 1994).  Coexpression of 
Fas and FasL in these tissues therefore raises the possibil- 
ity that the Fas system may be implicated in apoptotic cell 
death during physiological cell turnover. Evidence in sup- 
port of this hypothesis is provided by Ipr (lymphoprolifer- 
ation)  and  gld  (generalized  disease)  mice,  which  suffer 
from a large accumulation of nonmalignant CD4-CD8- T 
cells in the spleen and lymph nodes caused by defective 
Fas-mediated apoptosis. 
Alternatively, FasL expression in nonlymphoid tissues 
may be implicated in providing protection from immune 
damage caused by Fas-bearing T cells. It has recently been 
shown that FasL expression in the testis and eye confers 
an immune-privileged status to these tissues, thereby en- 
abling cell types expressing FasL to delete by apoptosis 
Fas-bearing T  cells that enter the tissue  (Bellgrau et al., 
1995; Griffith et al., 1995).  Several tissues other than the 
testis  and  eye  are  known  to  be  immune-privileged 
(Streilein, 1995).  Interestingly, several of these tissues, in- 
cluding the brain, testis, adrenal gland, uterus, ovary, and 
prostate, were shown by RNase protection analysis to ex- 
press the FasL gene. It therefore appears likely from this 
study, that in addition to the eye and testis, constitutive 
FasL  expression may also  be  implicated  in  the  mainte- 
nance  of an immune  privilege within  the brain,  adrenal 
gland, uterus, ovary, and prostate. Further investigations 
will be required to confirm this hypothesis. 
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